ctDNA and Emerging Biomarkers in Lung Cancer Treatment Decisions

This segment focuses on how ctDNA and an expanding set of molecular biomarkers are shaping modern lung cancer care. The panel explains that ctDNA provides real time molecular feedback that can help clinicians determine whether a treatment is still effective or if a change is required. By tracking specific mutations in the blood, oncologists can identify resistance mechanisms and adapt therapy more quickly.

The experts also discuss how gene panels are growing beyond single gene mutations to include complex alterations such as fusions, amplifications, and composite molecular signatures. These emerging biomarkers may soon guide not only targeted therapy but also immunotherapy selection and trial eligibility. The discussion emphasizes that while these tools add powerful new insights, they also require careful interpretation and collaboration across pathology, oncology, and molecular diagnostics.

This section reinforces that lung cancer care is increasingly driven by molecular data, with ctDNA and advanced biomarkers playing a central role in personalizing treatment.